<PAGE>

________________________________________________________________________________
________________________________________________________________________________


                      SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, D.C.   20549
                            ______________________

                                  FORM 10-Q

       ( X )   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
               SECURITIES EXCHANGE ACT OF 1934

                   FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1999.

       (    )  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
               SECURITIES EXCHANGE ACT OF 1934

               FOR THE TRANSITION PERIOD FROM __________ TO __________
                         COMMISSION FILE NUMBER: 0-21643
                         ______________________________

                            CV THERAPEUTICS, INC.
            (Exact name of Registrant as specified in its charter)


                 DELAWARE                             43-1570294
         (State of Incorporation)        (I.R.S. Employer Identification No.)


               3172 PORTER DRIVE, PALO ALTO, CALIFORNIA  94304
         (Address of principal executive offices, including zip code)

      Registrant's telephone number, including area code: (650) 812-0585

    Indicate by check whether the Registrant (1) has filed all reports to be
filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes   X     No

    The number of shares of Common Stock, $0.001 par value, outstanding as
of August 6, 1999 was 12,310,571.


________________________________________________________________________________
________________________________________________________________________________

<PAGE>

                        PART I.  FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

                                         CV THERAPEUTICS, INC.
                                      CONSOLIDATED BALANCE SHEETS
                          (in thousands, except share and per share amounts)
                                              (unaudited)
<TABLE>
<CAPTION>
                                                                               June 30,      December 31,
                                                                                 1999            1998
                                                                              ---------       ---------
                                                                              (unaudited)        (A)
<S>                                                                          <C>             <C>
                                               ASSETS
Current assets:
  Cash and cash equivalents                                                   $  7,769        $ 11,954
  Marketable securities                                                         30,358          32,850
  Other current assets                                                           1,124           1,236
                                                                              ---------       ---------
Total current assets                                                            39,251          46,040
Notes receivable from related parties                                              450             450
Property and equipment, net                                                      3,016           2,664
Intangible and other assets                                                         81             176
                                                                              ---------       ---------

Total Assets                                                                  $ 42,798        $ 49,330
                                                                              =========       =========

                                LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
  Accounts payable                                                            $    944        $  1,001
  Accrued liabilities                                                            2,899           2,761
  Current portion of long-term debt                                                  -           1,500
  Current portion of capital lease obligation                                       83              80
                                                                              ---------       ---------
Total current liabilities                                                        3,926           5,342
Long-term debt                                                                   7,500           7,500
Capital lease obligation                                                           295             338
Deferred revenue                                                                 1,000           1,000
Other long-term liabilities                                                        326             412
                                                                              ---------       ---------
Total liabilities                                                               13,047          14,592
Commitments
Stockholders' equity:
  Preferred stock, $0.001 par value, 5,000,000 shares authorized, none
       issued and outstanding                                                        -               -
  Common stock, $0.001 par value, 30,000,000 shares authorized, 12,310,571
       and 11,209,078 shares issued and outstanding at June 30, 1999 and
       December 31, 1998, respectively; at amounts paid in                     109,410         104,211
  Warrants to purchase common stock                                              1,225           1,225
  Notes receivable issued for stock                                                (87)           (108)
  Deferred compensation                                                           (727)         (1,049)
  Accumulated deficit                                                          (79,971)        (69,553)
  Cumulative other comprehensive income                                            (99)             12
                                                                              ---------       ---------
Total stockholders' equity                                                      29,751          34,738
                                                                              ---------       ---------

Total Liabilities and Stockholders' Equity                                    $ 42,798        $ 49,330
                                                                              =========       =========

</TABLE>

(A) Derived from the audited financial statements included in the Company's
    Annual Report on Form 10-K for 1998


                                       See accompanying notes

<PAGE>

                                                CV THERAPEUTICS, INC.
                                        CONSOLIDATED STATEMENTS OF OPERATIONS
                                      (in thousands, except per share amounts)
                                                     (unaudited)
<TABLE>
<CAPTION>
                                                        Three months ended June 30,        Six months ended June 30,
                                                         -------------------------         -------------------------
                                                            1999            1998              1999            1998
                                                         ---------       ---------         ---------       ---------
<S>                                                     <C>             <C>               <C>             <C>
Revenues:
  Collaborative research                                 $      -        $    299          $      -        $  4,482
Operating expenses:
  Research and development                                  4,477           3,589             8,676           6,925
  General and administrative                                1,173           1,109             2,357           2,117
                                                         ---------       ---------         ---------       ---------
Total operating expenses                                    5,650           4,698            11,033           9,042
                                                         ---------       ---------         ---------       ---------
Loss from operations                                       (5,650)         (4,399)          (11,033)         (4,560)
Interest income                                               523             738             1,098           1,455
Interest and other expense                                   (238)           (185)             (483)           (796)
                                                         ---------       ---------         ---------       ---------
Net loss                                                 $ (5,365)       $ (3,846)         $(10,418)       $ (3,901)
                                                         =========       =========         =========       =========
Basic and diluted net loss per share                     $  (0.45)       $  (0.35)         $  (0.90)       $  (0.37)
                                                         =========       =========         =========       =========
Shares used in computing basic and diluted
  net loss per share                                       11,907          11,073            11,569          10,647
                                                         =========       =========         =========       =========

</TABLE>
                                               See accompanying notes

<PAGE>

                                            CV THERAPEUTICS, INC.
                                    CONSOLIDATED STATEMENTS OF CASH FLOWS
                                               (in thousands)
                                                 (unaudited)
<TABLE>
<CAPTION>
                                                                        Six months ended June 30,
                                                                        -------------------------
                                                                           1999            1998
                                                                        ---------       ---------
<S>                                                                     <C>             <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss                                                                $(10,418)       $ (3,901)
Adjustments to reconcile net loss to net cash used in
  operating activities:
  Amortization of deferred compensation                                      318             371
  Depreciation and amortization                                              775             545
  Change in assets and liabilities:
    Other current assets                                                     112            (104)
    Intangible and other assets                                               95             378
    Accounts payable                                                         (57)            109
    Accrued and other liabilities                                             52           1,359
    Deferred revenue                                                           -          (5,009)
                                                                        ---------       ---------
Net cash used in operating activities                                     (9,123)         (6,252)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments                                                 (13,120)        (19,078)
Maturities of investments                                                 15,271          12,815
Capital expenditures                                                        (897)           (224)
Notes receivable from officers and employees                                  21               -
                                                                        ---------       ---------
Net cash used in investing activities                                      1,275          (6,487)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on capital lease obligations                                        (40)         (1,232)
Repayments of long-term debt                                              (1,500)           (500)
Net proceeds from issuance of common stock, net of repurchases             5,203          19,852
                                                                        ---------       ---------
Net cash provided by financing activities                                  3,663          18,120
                                                                        ---------       ---------
Net increase (decrease) in cash and cash equivalents                      (4,185)          5,381
Cash and cash equivalents at beginning of period                          11,954           6,286
                                                                        ---------       ---------
Cash and cash equivalents at end of period                              $  7,769        $ 11,667
                                                                        =========       =========

</TABLE>
                                            See accompanying notes

<PAGE>

                            CV THERAPEUTICS, INC.
                 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    Basis of Presentation

    The accompanying consolidated financial statements of CV Therapeutics,
Inc. have been prepared in accordance with generally accepted accounting
principles, are unaudited and reflect all adjustments (consisting solely of
normal recurring adjustments) which are, in the opinion of management,
necessary to present fairly the financial position at, and the results of
operations for the interim periods presented.  The results of operations for
the three- and six-month periods ended June 30, 1999 are not necessarily
indicative of the results to be expected for the entire year ending December
31, 1999 or for future operating results.  The financial information
included herein should be read in conjunction with the Company's Annual
Report on Form 10-K  for the year ended December 31, 1998 which includes the
audited consolidated financial statements and the notes thereto.

    Revenue Recognition

    Revenue under the Company's collaborative research arrangements is
recognized based on the performance requirements of the contract. Payments
received, which are still subject to future performance requirements, are
recorded as deferred revenue until earned.

    Net Loss Per Share

    Net loss per share is computed using the weighted average number of
common shares outstanding.  Common equivalent shares have been excluded from
the computation as their effect is antidilutive.

2.  COMPREHENSIVE LOSS

    The components of comprehensive loss for the six months ended June 30,
1999 and 1998 are as follows:

        <TABLE>
        <CAPTION>
                                                                1999            1998
                                                             ---------       ---------
        <S>                                                 <C>             <C>
        (in thousands)
        Net loss                                             $(10,418)       $ (3,901)
        Unrealized losses on marketable securities               (111)            (20)
                                                             ---------       ---------
        Comprehensive loss                                   $(10,529)       $ (3,921)
                                                             =========       =========

        </TABLE>


3.  LICENSE AND COLLABORATION AGREEMENTS

    In May 1999, the Company entered into a commercialization agreement with
Innovex Inc for the U.S. marketing and sales of ranolazine. If the product
is approved by the FDA, Innovex will provide CVT with a dedicated sales
force and will fund other sales and marketing expenses in return for up to
one-third of U.S. ranolazine revenues. Under the terms of the agreement
Innovex's parent company, Quintiles Transnational Corp., purchased $5.0
million of the Company's common stock.

<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

    This Management's Discussion and Analysis of Financial Condition and
Results of Operations and other parts of this Quarterly Report on Form 10-Q
contain forward-looking statements which involve risks and uncertainties.
The Company's actual results may differ materially from the results
discussed in the forward-looking statements. Factors that might cause such a
difference include, but are not limited to, those listed below and those
listed in "Risk Factors" in the Company's Annual Report on Form 10-K for the
year ended December 31, 1998.

OVERVIEW

    CVT is an early stage biopharmaceutical company focused on the
application of molecular cardiology to the discovery, development and
commercialization of novel small molecule drugs for the treatment of
cardiovascular disease. Since its inception in December 1990, substantially
all of the Company's resources have been dedicated to research and
development. To date, CVT has not generated any product revenue and does not
expect to generate any such revenues for at least three years. As of June
30, 1999, the Company had an accumulated deficit of $80.0 million. The
Company expects its sources of revenue, if any, for at least the next three
years to consist of payments under corporate partnerships and interest
income. The process of developing the Company's products will require
significant additional research and development, preclinical testing and
clinical trials, as well as regulatory approval. These activities, together
with the Company's general and administrative expenses, are expected to
result in operating losses for the foreseeable future. The Company will not
receive product revenue unless it or its collaborative partners complete
clinical trials and successfully commercialize one or more of its products.

    CVT is subject to risks common to biopharmaceutical companies, including
risks inherent in its research and development efforts and clinical trials,
reliance on collaborative partners, enforcement of patent and proprietary
rights, the need for future capital, potential competition and uncertainty
of regulatory approval. In order for a product to be commercialized, it will
be necessary for CVT and, in some cases, its collaborators, to conduct
preclinical tests and clinical trials, demonstrate efficacy and safety of
the Company's product candidates, obtain regulatory clearances and enter
into manufacturing, distribution and marketing arrangements, as well as
obtain market acceptance. There can be no assurance that the Company will
generate revenues or achieve and sustain profitability in the future.

RESULTS OF OPERATIONS

    Collaborative Research Revenues.  There were no collaborative research
revenues for the quarter ended June 30, 1999, compared to $299,000 for the
quarter ended June 30, 1998. There were also no collaborative research
revenues for the six-month period ended June 30, 1999, compared to $4.5
million for the six-month period ended June 30, 1998. The collaborative
research revenue for both the three and six-month periods ended June 30,
1998 was the result of the Company's completion of the research component of
its collaboration with Biogen during the first quarter of 1998.

    Research and Development Expenses.  Research and development expenses
increased to $4.5 million for the quarter ended June 30, 1999, compared to
$3.6 million for the quarter ended June 30, 1998. Research and development
expenses increased to $8.7 million for the six-month period ended June 30,
1999, compared to $6.9 million for the six-month period ended June 30, 1998.
The increases for both the three and the six-month periods ended June 30,
1999, compared to the same periods in 1998, were primarily due to hiring
additional employees to provide support for an increased level of activity
in the research, development and clinical programs. The Company expects
research and development expenses to continue to increase over the next
several years as the Company further expands product development efforts and
clinical trials.

<PAGE>

    General and Administrative Expenses.  General and administrative
expenses increased to $1.2 million for the quarter ended June 30, 1999,
compared to $1.1 million for the quarter ended June 30, 1998. General and
administrative expenses increased to $2.4 million for the six-month period
ended June 30, 1999, compared to $2.1 million for the six-month period ended
June 30, 1998. The increases for both the three and the six-month periods
ended June 30, 1999, compared to the same periods in 1998, were primarily
due to an increase in outside legal expenses for a variety of administrative
and corporate matters. The Company expects general and administrative
expenses to increase in the future in line with the Company's research and
development activities.

    Interest Income/Interest and Other Expense.  Interest income was
$523,000 for the quarter ended June 30, 1999, compared to $738,000 for the
quarter ended June 30, 1998. Interest income was $1.1 million for the
six-month period ended June 30, 1999, compared to $1.5 million for the
six-month period ended June 30, 1998. The decreases for both the three and
the six-month periods ended June 30, 1999, compared to the same periods in
1998, were due to lower average investment balances. Interest and other
expense was $238,000 for the quarter ended June 30, 1999 compared to
$185,000 for the quarter ended June 30, 1998. Interest and other expense was
$483,000 for the six-month period ended June 30, 1999 compared to $796,000
for the six-month period ended June 30, 1998. The increase for the quarter
ended June 30, 1999, compared to the same period in 1998, was primarily due
to interest expense associated with a $4.5 million addition to the loan
balance with Biogen, Inc. in December 1998. The decrease for the six-month
period ended June 30, 1999, compared to the same period in 1998, was
primarily due to a charge of $371,000 recognized during the first quarter of
1998 related to the early retirement of a capital lease obligation. The
Company expects that interest income/interest and other expense will
fluctuate with average investment and loan balances.

LIQUIDITY AND CAPITAL RESOURCES

    The Company has financed its operations since inception primarily
through private placements of preferred and common stock, public offerings
of common stock, equipment and leasehold improvement financing, other debt
financing and payments under corporate collaborations. In November 1996, the
Company completed an initial public offering and raised net proceeds of
approximately $12.0 million. In March 1997, the Company entered into two
research collaboration and license agreements with Biogen that together
resulted in cash receipts of $16.0 million. In October 1997, the Company
raised net proceeds of $12.3 million in a private placement of equity
securities with BB Biotech. In January 1998, the Company completed a
follow-on public offering and raised net proceeds of approximately $19.6
million.  In December 1998, the Company drew down an additional $4.5 million
under a general purpose loan facility with Biogen. As of June 30, 1999 the
outstanding balance for this note was $7,500,000. Interest on this note is
payable at prime plus one and one-half percent (1.5%) (9.25% at June 30,
1999) payable annually, in arrears, each March 10th. In May 1999, the
Company entered into a commercialization agreement with Innovex Inc.
pursuant to which Innovex's parent, Quintiles Transnational Corp., purchased
1,043,705 shares of the Company's common stock for a total investment
of $5.0 million. In addition, the Company entered into two promissory notes
with Quintiles Transnational Corp. The first promissory note in the amount of
$10.0 million may be drawn down by the Company at NDA filing of ranolazine.
The second promissory note shall be for a cash amount to be determined after
commercial launch of ranolazine. Both notes are convertible into shares of
common stock at the option of Quintiles upon certain events.

    Cash, cash equivalents and marketable securities at June 30, 1999
totaled $38.1 million compared to $44.8 million at December 31, 1998. The
decrease in the first six months of 1999 was due to the funding of ongoing
operations offset by the $5.0 million received from the Quintiles
Transnational Corp. stock purchase.

    Net cash used in operations for the six months ended June 30, 1999 was
$9.1 million compared to $6.3 million for the six months ended June 30,
1998. The increase in cash used in operations for the first six months of
1999, compared to the first six months of 1998, was primarily due to
increased research and development efforts.

<PAGE>

    As of June 30, 1999, the Company has invested $8.2 million in property
and equipment with the rate of investment having increased last year in line
with increased research and development efforts. This trend should continue
for the foreseeable future.

    The Company will require substantial additional funding in order to
complete its research and development activities and commercialize any
potential products.  The Company currently estimates that its existing
resources and projected interest income will enable the Company to maintain
its current and planned operations through the end of 2000. However, there
can be no assurance that the Company will not require additional funding
prior to such time or that additional financing will be available on
acceptable terms or at all.

    The Company's forecast of the period of time through which its financial
resources will be adequate to support its operations is a forward-looking
statement that involves risks and uncertainties, and actual results could
vary as a result of a number of factors. The Company's future capital
requirements will depend on many factors, including scientific progress in
its research and development programs, the size and complexity of such
programs, the scope and results of preclinical studies and clinical trials,
the ability of the Company to establish and maintain corporate partnerships,
the time and costs involved in obtaining regulatory approvals, the costs
involved in filing, prosecuting and enforcing patent claims, competing
technological and market developments, the  cost of manufacturing
preclinical and clinical material and other factors not within the Company's
control. There can be no assurance that such additional financing to meet
the Company's capital requirements will be available on acceptable terms or
at all. Insufficient funds may require the Company to delay, scale back or
eliminate some or all of its research or development programs, to lose
rights under existing licenses or to relinquish greater or all rights to
product candidates at an earlier stage of development or on less favorable
terms than the Company would otherwise choose or may adversely affect the
Company's ability to operate as a going concern. If additional funds are
raised by issuing equity securities, substantial dilution to existing
stockholders may result.

YEAR 2000

    Many computer systems, applications, information technologies and
equipment containing computer related components (generally "computer
systems and equipment") are unable to differentiate between the year 2000
and the year 1900 because they were programmed with two-digit, rather than
four-digit, date fields. Accordingly, older computer systems that have
time-sensitive applications may not properly recognize the year 2000 and
beyond ("Year 2000 issue"). This could cause system or equipment shut downs,
failures or miscalculations resulting in inaccuracies in computer output or
disruptions of operations, including, among other things, inaccurate
processing of financial information and/or temporary inabilities to process
transactions, manufacture products, or engage in similar normal business
activities.

    The Company has formed a committee to assess the impact of the problem
on the Company's operations; however, the committee's assessment of the Year
2000 issue is not yet complete. The Company tested its key computer systems
and equipment (including financial, informational and operational systems)
and determined that these systems were largely Year 2000 compliant. The
Company has completed upgrades to the systems which it determined were not
Year 2000 compliant. The Company believes that with these upgrades, the Year
2000 issue will not pose significant operational problems for its computer
systems and equipment. The Company currently has no contingency plans to
deal with major Year 2000 failures.

    In addition to risks associated with the Company's own computer systems
and equipment, the Company has relationships with, and is to varying degrees
dependent upon, a large number of third parties that provide information,
goods and services to the Company. These include financial institutions,
suppliers, vendors, research partners and governmental entities. If
significant numbers of these third parties experience failures in their
computer systems, or equipment due to the Year 2000 issue, these failures
could affect the Company's ability to process transactions, manufacture
products, or engage in similar normal business activities. While some of
these risks are outside of the Company's control, the Company has instituted
programs, including internal records review and use of external

<PAGE>

questionnaires, to identify key third parties, assess their level of Year
2000 compliance, update contracts and address any non-compliance issues. As
of June 30 1999 a majority of the key third parties have responded that they
are or will be Year 2000 compliant by December 31, 1999. The remaining key
third parties were sent a follow-up questionnaire in June 1999.

    The total cost of the Year 2000 systems assessment and upgrades is
funded through operating cash flows and the Company is expensing these
costs. The financial impact of making the required systems changes is
minimal and currently expected to be approximately $30,000. The actual
financial impact could, however, exceed this estimate.

ADDITIONAL FACTORS THAT MAY AFFECT FUTURE RESULTS

    The Company's business, financial condition and results of operations
are subject to various risks, including those described below and elsewhere
in this Quarterly Report on Form 10-Q.

    The Company is an early stage company and must be evaluated in light of
the uncertainties and complications present in an early stage
biopharmaceutical company.  All of the Company's products are at an early
stage of development, and the Company has not generated any product revenue.
 In addition, the Company has only three products in clinical development,
ranolazine (phase III), CVT-124 (phase II) and CVT-510 (phase I).  There can
be no assurance that clinical trials conducted by the Company or its
collaborators will demonstrate sufficient safety and efficacy to obtain the
requisite approvals or that marketable products will result.  In addition,
the rate of completion of clinical trials may be delayed by many factors.
The Company's product candidates will require significant additional
development, preclinical studies, clinical trials and regulatory approval
prior to commercialization.  These activities may take several years and
require the expenditure of substantial resources.  In addition, these
activities, together with the Company's general and administrative expense,
are expected to result in operation losses for the foreseeable future.

    The Company's strategy for the research, development and
commercialization of its product candidates has required, and will continue
to require, the Company to enter into various arrangements with corporate
and academic collaborators, licensors, licensees and others, and the Company
is dependent upon the success of these parties in performing their
responsibilities.  There can be no assurance that the Company will be able
to enter into additional collaborative arrangements or license agreements on
acceptable terms, or at all, or that the contemplated benefits from any of
these agreements will be realized.

    The Company's business is affected by other factors, including:
uncertainty of market acceptance, intense competition and rapid
technological change, uncertainty of patent position and proprietary rights,
dependence on key personnel and the need to attract and retain key employees
and consultants, limited manufacturing, marketing and sales experience,
significant government regulation, uncertainty of product pricing and
reimbursement, product liability exposure and the availability of insurance.

<PAGE>

                         PART II.  OTHER INFORMATION

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

    On May 5, 1999, the Company issued and sold 1,043,705 shares of its
common stock to Quintiles Transnational Corp. for a total purchase price of
$5.0 million. In addition, the Company entered into two promissory notes with
Quintiles Transnational Corp. The first promissory note in the amount of
$10.0 million may be drawn down by the Company at NDA filing of ranolazine.
The second promissory note shall be for a cash amount to be determined after
commercial launch of ranolazine. Both notes are convertible into shares of
common stock at the option of Quintiles upon certain events. The sale of the
shares of common stock and the promissory notes were deemed exempt form the
registration requirements of the Securities Act of 1333, as amended, by virtue
of Regulation D promulgated thereunder.

ITEM 3. MARKET RISK

    The Company's exposure to market rate risk for changes in interest rates
relates primarily to the Company's investment portfolio. As of June 30, 1999
no significant changes have occurred since the Company's Annual Report on
Form 10-K for the year ended December 31, 1999.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

    (a)     The Annual Meeting of Stockholders of CV Therapeutics, Inc. was
            held on May 11, 1999.

    (b)     David P. Holveck, Barbara J. McNeil, M.D., Ph.D. and J. Leighton
            Read, M.D. were elected to the Board of Directors. The terms of
            Louis G. Lange, M.D., Ph.D., Thomas L. Gutshall, Costa G.
            Sevastopoulos, Ph.D. and Issac Stein continued after the Annual
            Meeting.

Election of Directors:


             Nominee                       For                  Withheld

      David P. Holveck                  6,137,389                800,463
      Barbara A. McNeil, M.D., Ph.D.    6,137,889                799,963
      J. Leighton Read, M.D.            6,137,889                799,963

Proposal to ratify the selection of Ernst & Young LLP as independent
auditors of the Company for its fiscal year ending December 31, 1999:

              For                        Against                 Abstain

           6,918,171                      13,411                  6,270

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

    (c)     Exhibits required by Item 601 of Regulation S-K

        EXHIBIT NUMBER                            DESCRIPTION

            10.65*                      Stock Purchase Agreement dated
                                        May 5, 1999 between the Company
                                        and Quintiles Transnational Corp.

<PAGE>

            10.66*                      Sales and Marketing Services
                                        Agreement dated May 5, 1999
                                        between the Company, Innovex
                                        Inc. and Quintiles
                                        Transnational Corp.

            10.67*                      Loan Agreement dated May 5,
                                        1999 between the Company and
                                        Quintiles Transnational Corp.

            10.68*                      Security Agreement dated May 5,
                                        1999 between the Company and
                                        Quintiles Transnational Corp.

            10.69                       Promissory Note dated May 5,
                                        1999 to Quintiles in principal
                                        amount of $10.0 million.

            10.70                       Promissory Note dated May 5,
                                        1999 to Quintiles Transnational
                                        in principal amount specified
                                        therein.

            10.71                       Amendment to Loan Agreement
                                        dated April 30, 1999 between
                                        the Company and Biotech
                                        Manufacturing Ltd.

            27.1                        Financial Data Schedule

       * Confidential treatment is being sought for portions of this
       exhibit. Brackets indicate portions of the text that have been
       omitted. A separate filing of such omitted text has been made
       with the Commission as part of the Company's application for
       confidential treatment.

    (d)     Reports on Form 8-K

            The Company filed a current report on Form 8-K with the
            Commission on May 19, 1999, with respect to a commercial
            arrangement with Quintiles Transnational Corp. to commercialize
            ranolazine.

<PAGE>

                                  SIGNATURES

    Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf, by the undersigned, thereunto duly authorized.

                                                      CV THERAPEUTICS, INC.

Date: August 16, 1999               By: /s/ LOUIS G. LANGE, M.D., PH.D.
                                            Louis G. Lange, M.D., Ph.D.
                                 Chairman of the Board & Chief Executive Officer
                                           (Principal Executive Officer)


Date: August 16, 1999               By: /s/ DANIEL K. SPIEGELMAN
                                            Daniel K. Spiegelman
                                           Chief Financial Officer
                                  (Principal Financial and Accounting Officer)